NEULAND LABORATORIES
|
NEULAND LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 283.71 | 202.74 | 233.89 | 127.45 | 49.74 |
| CEPS(Rs) | 355.22 | 253.82 | 280.42 | 168.59 | 87.97 |
| DPS(Rs) | 34.00 | 12.00 | 14.00 | 10.00 | 5.00 |
| Book NAV/Share(Rs) | 1,460.31 | 1,187.77 | 999.07 | 774.12 | 654.40 |
| Tax Rate(%) | 25.56 | 24.90 | 25.25 | 24.21 | 22.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 28.40 | 21.89 | 29.68 | 22.82 | 15.00 |
| EBIT Margin(%) | 25.35 | 24.01 | 26.65 | 19.21 | 10.06 |
| Pre Tax Margin(%) | 24.17 | 23.45 | 25.76 | 18.11 | 8.64 |
| PAT Margin (%) | 17.99 | 17.61 | 19.25 | 13.73 | 6.71 |
| Cash Profit Margin (%) | 22.53 | 22.05 | 23.08 | 18.16 | 11.87 |
| Performance Ratios | |||||
| ROA(%) | 14.25 | 12.97 | 17.59 | 11.04 | 4.71 |
| ROE(%) | 21.43 | 18.54 | 26.38 | 17.84 | 7.85 |
| ROCE(%) | 27.50 | 23.45 | 33.51 | 20.94 | 9.44 |
| Asset Turnover(x) | 0.79 | 0.74 | 0.91 | 0.80 | 0.70 |
| Sales/Fixed Asset(x) | 1.46 | 1.28 | 1.54 | 1.28 | 1.09 |
| Working Capital/Sales(x) | 2.62 | 2.19 | 3.16 | 3.70 | 4.37 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.68 | 0.78 | 0.65 | 0.78 | 0.91 |
| Receivable days | 77.32 | 85.17 | 86.10 | 91.33 | 86.74 |
| Inventory Days | 80.83 | 90.97 | 73.73 | 83.41 | 98.40 |
| Payable days | 125.94 | 137.94 | 114.75 | 110.05 | 116.52 |
| Valuation Parameters | |||||
| PER(x) | 42.34 | 59.57 | 26.86 | 14.12 | 20.64 |
| PCE(x) | 33.82 | 47.58 | 22.40 | 10.67 | 11.67 |
| Price/Book(x) | 8.23 | 10.17 | 6.29 | 2.32 | 1.57 |
| Yield(%) | 0.28 | 0.10 | 0.22 | 0.56 | 0.49 |
| EV/Net Sales(x) | 7.54 | 10.41 | 5.15 | 1.99 | 1.61 |
| EV/Core EBITDA(x) | 25.23 | 44.72 | 16.89 | 8.42 | 10.56 |
| EV/EBIT(x) | 29.74 | 43.35 | 19.32 | 10.36 | 15.97 |
| EV/CE(x) | 7.37 | 9.26 | 5.88 | 2.13 | 1.43 |
| M Cap / Sales | 7.62 | 10.49 | 5.17 | 1.94 | 1.38 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 36.98 | -5.24 | 30.84 | 25.25 | 1.51 |
| Core EBITDA Growth(%) | 75.89 | -27.65 | 68.73 | 94.61 | -11.18 |
| EBIT Growth(%) | 44.64 | -14.64 | 81.56 | 139.20 | -22.38 |
| PAT Growth(%) | 39.94 | -13.32 | 83.51 | 156.21 | -20.85 |
| EPS Growth(%) | 39.94 | -13.32 | 83.51 | 156.21 | -20.85 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.10 | 0.09 | 0.06 | 0.12 | 0.28 |
| Current Ratio(x) | 2.09 | 2.45 | 2.15 | 1.73 | 1.60 |
| Quick Ratio(x) | 1.37 | 1.62 | 1.33 | 1.10 | 0.87 |
| Interest Cover(x) | 21.42 | 42.74 | 29.68 | 17.51 | 7.09 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | 0.01 | 0.05 | 0.18 |
Compare Financial Ratios of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹24,981.4 Cr | 3.5% | 15.3% | 67.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹464,331.0 Cr | 1.2% | 8.3% | 15.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹181,466.0 Cr | -0.2% | 3% | -0.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹165,952.0 Cr | 1.7% | 9.9% | 46.8% | Stock Analytics | |
| CIPLA | ₹116,229.0 Cr | -2.2% | 4.5% | -4.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,959.0 Cr | -9% | -2.1% | -1.8% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 3.5% |
15.3% |
67.6% |
| SENSEX | -0.3% |
4.9% |
-7% |
You may also like the below Video Courses
